

Our Vision:

To be the World Leader in the Bio-analytical testing market


Our Mission:

To contribute to global health and safety by providing our customers with high quality laboratory and advisory services whilst creating opportunities for our employees and generating sustainable shareholder value.

Our Values:

Achievement of our Mission is based on Eurofins "**Core Values**", which commit us to *Customer focus, Quality, Competence & Team Spirit and Integrity*

EBITDA in € Million



Eurofins shares are listed on Euronext Paris Stock Exchange (IPO 1997)

ISIN FR0000038259

Reuters EUFI.LN

Bloomberg ERSC FP

Index SBF 250, MidCAC 100, Next 150

Member of the NextEconomy segment

Share price performance as of 31 May 2007:

- vs. IPO (10/1997) : over +3,500%
- over the last 12 months : +29%

and Deutsche Börse Frankfurt (SPO 2000)

WPKN 910251

Reuters EUFI.DE

Contacts

Dr. Gilles G. Martin, CEO

Dr. Matthias-Wilbur Weber, CFO

Hugues Vaussy, Finance Director Holding

Stuart Morgan, Investor Relations

Addresses

Rue Pierre Adolphe Bobierre - BP 42301

F- 44323 NANTES Cedex 3 - France

Chaussée de Malines 455

B- 1950 Kraainem (Brussels) - Belgium

Contact details

Tel (+32) 2 766 16 20

Fax(+32) 2 766 16 32

ir@eurofins.com

www.eurofins.com

Company Profile

Eurofins Scientific is a life sciences company operating laboratories in 24 countries to provide a comprehensive range of analytical testing services drawing on the latest developments in biotechnology. The Group specialises in delivering analytical testing and advisory services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With about \$ 500 million in annual sales, Eurofins believes it is the global leader in food testing, belongs to the leading global laboratory groups serving the pharmaceutical industry and is number one in Europe in the environmental testing field.

Short History

Eurofins Scientific was founded in 1987 to market the SNIF-NMR[®] technology, a patented analytical method used to verify the origin and purity of several types of food and beverages in cases where traditional testing methods would fail to detect a sophisticated fraud. Within a 20-year period, the Group has grown from a start-up company with 12 employees to become an international network of over 90 laboratories located in Europe, the USA, Asia and South-America employing more than 5,000 staff.

With a portfolio of over 15,000 reliable analytical methods and performing more than 80 million assays per year to establish the safety, composition, authenticity, origin, traceability, identity and purity of biological substances, the Eurofins Group is now a leading global provider of bioanalytical services.

Eurofins is one of the fastest growing companies in Europe: since its IPO on the French stock exchange in 1997, Eurofins' sales have increased by more than 50% each year (in compound average) to € 368 m in 2006. The shares of Eurofins Scientific are traded on Euronext (Paris) and Deutsche Börse/XETRA (Frankfurt). Eurofins belongs to the Euronext index SBF 250, MidCAC 100, and Next150 and thus ranks amongst the largest 250 companies listed in Paris, Amsterdam, Brussels and Lisbon.

Recent Developments

During the past year, Eurofins acquired several new laboratories mainly in Germany, Scandinavia, France and the UK and with the acquisitions of Chemical Control and Biolab the Company entered the Italian market. Eurofins established a Wholly-Foreign-Owned Enterprise in China and took a major stake in the Japanese company Fasmac to create a basis for providing analytical services to customers in the Far-East. The Group's Central Laboratory network Eurofins | Medinet recently expanded significantly by building up two new sites in Singapore and the USA.

These activities enabled Eurofins to strengthen its position in the food and pharmaceutical testing sectors as well as in the field of DNA, genotyping and clinical trials. The Group has enhanced its offer to the pharmaceutical and biotechnological industries and now spans almost all of the product development cycle. The Group has become one of Europe's largest Contract Research Organisation providers for the pharmaceutical, agro-pharmaceutical and biotechnological industries.

Eurofins has established several world-class Competence Centres and believes it is the global leader in the analysis for trace amounts of dioxins and Persistent Organic Pollutants as well as in testing for Genetically Modified Organisms (GMO). This structure, combined with a broad test portfolio and technical expertise has allowed the Group to react quickly to protect its clients from recent food and feed scares (e.g. food and feed contamination with veterinary residues, forbidden dyes, melamine and unauthorised GMO). Eurofins has developed many new analytical testing methods and has participated in or led several R&D projects in association with government bodies, industry and universities.

Future Plans

Eurofins intends to strengthen its global position as a leading bioanalysis laboratory group serving the pharmaceutical, food and environmental industries. Eurofins aims to become a global market leader in this field of applied life sciences.

The Group is committed to supporting its clients' objectives of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate. Eurofins intends to continue to develop, acquire or license the most comprehensive range of state-of-the-art analytical technologies as well as expand its geographical reach in order to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.